company background image
INDSWFTLAB logo

Ind-Swift Laboratories NSEI:INDSWFTLAB Stock Report

Last Price

₹107.00

Market Cap

₹6.3b

7D

0.3%

1Y

6.1%

Updated

25 Dec, 2024

Data

Company Financials

Ind-Swift Laboratories Limited

NSEI:INDSWFTLAB Stock Report

Market Cap: ₹6.3b

INDSWFTLAB Stock Overview

Develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. More details

INDSWFTLAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Rewards

Price-To-Earnings ratio (1.7x) is below the Indian market (32.3x)

Earnings grew by 628.3% over the past year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap (₹6B)


My Notes

Capture your thoughts, links and company narrative

Ind-Swift Laboratories Limited Competitors

Accent Microcell

NSEI:ACCENTMIC

₹5.8b

Jenburkt Pharmaceuticals

BSE:524731

₹5.4b

ZIM Laboratories

BSE:541400

₹5.5b

Sakar Healthcare

NSEI:SAKAR

₹6.6b

Price History & Performance

Summary of share price highs, lows and changes for Ind-Swift Laboratories
Historical stock prices
Current Share Price₹107.00
52 Week High₹186.00
52 Week Low₹86.20
Beta0.37
1 Month Change8.49%
3 Month Change-18.18%
1 Year Change6.10%
3 Year Change57.01%
5 Year Change347.70%
Change since IPO496.10%

Recent News & Updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20
Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20
Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21
Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28
Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12
Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17
Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30
We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Shareholder Returns

INDSWFTLABIN PharmaceuticalsIN Market
7D0.3%1.3%-3.2%
1Y6.1%39.0%18.7%

Return vs Industry: INDSWFTLAB underperformed the Indian Pharmaceuticals industry which returned 39% over the past year.

Return vs Market: INDSWFTLAB underperformed the Indian Market which returned 18.7% over the past year.

Price Volatility

Is INDSWFTLAB's price volatile compared to industry and market?
INDSWFTLAB volatility
INDSWFTLAB Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.1%

Stable Share Price: INDSWFTLAB has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: INDSWFTLAB's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199547Navrattan Munjalwww.indswiftlabs.com

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.

Ind-Swift Laboratories Limited Fundamentals Summary

How do Ind-Swift Laboratories's earnings and revenue compare to its market cap?
INDSWFTLAB fundamental statistics
Market cap₹6.32b
Earnings (TTM)₹3.73b
Revenue (TTM)₹7.42b

1.7x

P/E Ratio

0.9x

P/S Ratio

Is INDSWFTLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDSWFTLAB income statement (TTM)
Revenue₹7.42b
Cost of Revenue₹3.90b
Gross Profit₹3.52b
Other Expenses-₹214.46m
Earnings₹3.73b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 14, 2025

Earnings per share (EPS)63.20
Gross Margin47.41%
Net Profit Margin50.30%
Debt/Equity Ratio1.6%

How did INDSWFTLAB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ind-Swift Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hitesh KuvelkarFirst Global Stockbroking (P) Ltd.